


VEEDA COMPLETES 20th PATIENT BASED PHARMACOKINETIC STUDY SUCCESSFULLY.

We are happy to inform you that recently we have completed 20th patient based Pharmacokinetic study. This has been achieved by our dedicated team of experienced professionals and an elaborate network of experienced Clinical Trial sites across India.

The team has overseen the enrolment of **818 patients** from **103 sites** across India in therapeutic areas such as Oncology, Psychiatry, HIV, Rheumatology and Dermatology. In addition, the team is currently working on 11 patient PK studies which are in different stages of execution for targeted enrollment of **553 patients** in Oncology, Psychiatry and Respiratory therapeutic areas.

Completed patient based Pharmacokinetic Studies

Therapeutic area	Molecule	Indication	No. of studies	Total patient enrolled
Oncology	Etoposide 50 mg Cap	Small cell lung cancer	1	24
	Imatinib 400 mg Tab	Chronic Myeloid Leukemia	7	232
	Capacitabine 500 mg Tab	Metastatic Breast Cancer and Colorectal cancer	1	54
	Doxorubicin Hcl (Pegylated liposomal)	Ovarian & Breast Cancer	2	79
	Paclitaxel 100 mg/vial	Metastatic Breast Cancer	1	76
	Everolimus 10 mg Tab	Renal Cell Carcinoma	1	30
Rheumatology and Dermatology	Methotrexate 2.5 mg Tab	Rheumatoid Arthritis and Psoriasis	1	42
Psychiatry	Quetiapine 400 mg and 600 mg ER tab	Schizophrenia	2	116
	Paliperidone PR 9 mg Tab	Schizophrenia	1	75
	Clozapine Tab 100 mg and 25 mg	Schizophrenia	2	42
HIV	Nevirapine Tab 400 mg	HIV-1 Infection	1	48



Our patient based Pharmacokinetic studies capabilities:

- In last 3 years, Veeda successfully faced sixteen (16) USFDA inspections at Investigator sites (where Veeda conducted PK studies)
- Proven track record of timely recruitment completion even for rare indications such as RCC and SCLC
- Done detailed feasibility for 45 molecules for patient based pharmacokinetic studies and has a roadmap ready for these molecules.
- Dynamic database of more than 700 experienced Investigators across various therapeutic areas with good recruitment potential.